Sterile manufacturing expert Symbiosis Pharmaceutical Services has bolstered its project management and manufacturing teams with the appointment of several new staff to support its ongoing growth.
The fast-growing contract manufacturing organisation (CMO) has increased employee numbers by around 35% over the last 18 months and expects this to continue in 2016 as the Scotland-based company continues to expand.
Symbiosis specialises in the sterile fill/finish of biologic and small molecule products into vials for pharmaceutical and biotechnology drug development companies. The decision to reinforce its project management and production departments was taken to sustain and enhance service levels with increasing numbers of clients and projects.
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: “We have grown considerably over the last year so it’s essential that we have the right people and skills in place to cope with the next phase of the company’s development.
“As we continue to expand as a business and grow into new markets, its imperative that we maintain what made us different in the first place in terms of managing client projects efficiently by giving them rapid access to manufacturing slots.”
As part of its recruitment drive, the CMO appointed a project management director to join its senior team. Niall Henderson joined in a newly created role and is now responsible for managing the project management department.
Colin added: “We were delighted to add another experienced industry professional of Niall’s calibre to our management team to help us deliver world-class sterile manufacturing services.
“He is providing leadership to the project management function, helping ensure the team plays a vital role in the delivery of clients’ projects in line with agreed milestones and timeframes.”
Niall has worked in the pharmaceutical sector for almost 20 years in both big pharma companies and across the contract services sector, working to GLP, cGMP and ISO standards. A trained microbiologist and Chartered Biologist, he was attracted to Symbiosis by its growth and vision.
He said: “I was aware of Symbiosis through its burgeoning reputation in the marketplace and once I had the opportunity to speak to Colin, I was instantly impressed with his vision and knew it was a good time to join the company.
“I am already enjoying the responsibility and freedom of being able to shape my department and introduce refinements to the way projects are managed to further improve client experience and project delivery. This is a company on a very exciting journey so I am thrilled to be part of it.”
Symbiosis is currently undertaking a major investment initiative at its sterile filling facility following increased demand for its small-scale sterile filling services and to ensure continued compliance with the latest interpretation of the guidelines by the MHRA.
This latest expansion enables the business to aseptically manufacture and provide lyophilization services at both the clinical stage and for clients with niche licensed commercial products.
By pharmaceutical PR agency, ramarketing.